Four new directors at TherapeuticsMD
This article was originally published in Scrip
Executive Summary
Specialty pharma company TherapeuticsMD, which focuses on products primarily for the women's healthcare market, has elected four new members to its board of directors: Samuel Greco, currently CEO and director of CareView Communications; Cooper Collins, president, CEO and director of Pernix Therapeutics Holdings; Robert LaPenta, a partner of Aston Capital; and Nicholas Segal, director of Seavest Capital Partners.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.